- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03654963
Study to Assess the Impact of Medication Reconciliation at Hospital Admission on Healthcare Outcomes (MedRec)
Parallel Group Randomized Controlled Trial to Assess the Impact of Medication Reconciliation at Hospital Admission on Healthcare Outcomes
Medication reconciliation is a systematic process by which health care professionals obtain the most complete and accurate information about the drugs regularly taken by patients. Internationally, the value of this procedure is mainly attributed to the reduction in the number of adverse drug events, which can cause drug-related morbidity and mortality, as well as unnecessary health care costs.
As part of the Progress! Pilot project Safe Pharmacotherapy at the interface points, promoted by the Federal Office of Public Health, coordinated by the Swiss Patients Safety Foundation and held in several Swiss hospitals, medication reconciliation at hospital admission was introduced at the regional hospital Beata Vergine in Mendrisio, from 2014 to 2016. During this pilot project it was shown that medication reconciliation after obtaining the best possible medication history by a pharmacist at hospital admission, in comparison with the standard medication history obtained by the physician at admission, reduced the number of clinically relevant drug discrepancies.
A structured, well-established and practicable procedure of medication reconciliation that improves patient safety assuring a better quality of care at hospital admission might provide evidence that medication reconciliation could be a valuable intervention to be applied systematically in all EOC hospitals at admission, as well as subsequently potentially at the other hospital interfaces.
The purpose of this study is to evaluate whether obtaining the best possible medication history and performing medication reconciliation at hospital admission results in improving some specific healthcare outcomes.
The study seeks primarily to determine if obtaining the best possible medication history and performing medication reconciliation, in comparison with the standard medication history, reduces the number of subsequent unplanned all-cause hospital visits (readmissions and emergency department visits within 30 days after initial discharge). As secondary objectives, the study aims at assessing if best possible medication history with medication reconciliation, in comparison with the standard medication history, reduces the incidence of adverse drug reactions during hospital stay, shortens length of stay, leads to a reduction in the use of hospital resources, and/or is associated with a decreased number of deaths.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients of the control group will not receive the best possible medication history with medication reconciliation at admission. The standard physician-acquired medication history will be performed as usual.
Eligible patients, randomized within the intervention arm, will receive medication reconciliation according to the following steps:
- The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking and details about how the drugs are taken. In order to confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members, in addition to referral letters, prescriptions and drug lists from primary care centres, and other.
- The clinical pharmacist will reconcile best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor.
- The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient providing complete information on medicines.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Locarno, Switzerland, 6600
- Regional Hospital La Carità
-
Mendrisio, Switzerland, 6850
- Regional Hospital Beata Vergine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients admitted to the inpatient wards of the two regional hospitals Beata Vergine in Mendrisio and La Carità in Locarno, fulfilling one of the following inclusion criteria, will be eligible for the study:
- patients aged ≥ 85 years
- patients with > 10 drugs at admission
Patients with home care as well as patients from elderly homes, meeting the inclusion criteria, will be factored in the study population.
Eligible patients will be included one-time only.
Exclusion Criteria:
The presence of any of the following exclusion criteria will lead to patient exclusion:
- patients admitted to intensive care unit who do not reach inpatient wards
- patients who are planned to stay within inpatient wards for less than 48 hours
- patients who have been admitted to any of the EOC hospital wards within the previous 3 months and have been discharged at home
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
Patients of the control group will not receive the best possible medication history with medication reconciliation at admission.
The standard physician-acquired medication history will be performed as usual.
|
|
Experimental: Medication reconciliation
The pharmacy assistant will obtain the best possible medication history by compiling a comprehensive list of the medications the patient is taking.
To confirm the accuracy of the history, the pharmacy assistant will use at least two sources of information, one of which being, when possible, the interview with the patient and/or family members.
The clinical pharmacist will reconcile the best possible medication history with prescribed medicines and, to resolve unclear or ambiguous discrepancies between the two lists and/or to propose any adaptations of the pharmacotherapy, the clinical pharmacist will refer to the medical doctor.
The medical doctor will decide potential changes in pharmacotherapy and communicate them to the patient.
|
Medication reconciliation is the systematic process described above.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite post-discharge healthcare use variable
Time Frame: Within 30 days after initial discharge
|
Total number of unplanned all-cause hospital visits (readmissions and emergency department visits within 30 days after initial discharge).
|
Within 30 days after initial discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of ADRs during hospital stay
Time Frame: 1 year
|
To measure the incidence of ADRs developed by patients during the hospital stay, the active pharmacovigilance system currently in use at the Centro Regionale di Farmacovigilanza del Canton Ticino, will be exploited.
EMRs identified through this system and referring to patients from both the two study sites, aged ≥85 years or with more than 10 medications at admission, will be manually validated (to discard false positive cases).
Subsequently, ADRs will be categorized as not serious or serious (according to the WHO seriousness criteria, for resulting in death, being life threatening, prolonging hospitalization, resulting in persistent disability or incapacity and other).
Outcome assessor will be masked to group allocation.
At the end of the analysis, ADRs will be matched to either the intervention or the control group
|
1 year
|
Length of hospital stay
Time Frame: 1 year
|
1 year
|
|
Death during hospital stay
Time Frame: 1 year
|
1 year
|
|
Number of resources used during hospital stay
Time Frame: 1 year
|
Laboratory tests, radiologic exams, echocardiography, electrocardiograms
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Dr med Alessandro Ceschi, PD, FEAPCCT, Institute of Pharmacological Science of Southern Switzerland, Ente Ospedaliero Cantonale
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 01 (Miami VAHS)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety Issues
-
Chulalongkorn UniversityNot yet recruiting
-
IC-MedTech CorporationRecruiting
-
Showa Inan General HospitalRecruiting
-
Asmaa Elwan Mohammed HassanCompleted
-
Hadassah Medical OrganizationGals Bio Ltd.Withdrawn
-
Federico II UniversityCompleted
-
Institute of Nuclear Energy Research, TaiwanCompleted
-
University of JordanCompleted
-
Hospital Universitario La FeSENSAR (Sistema español de notificación en seguridad en anestesia y reanimación)Completed
Clinical Trials on Medication reconciliation
-
US Department of Veterans AffairsIcahn School of Medicine at Mount Sinai; University of VictoriaCompleted
-
VA Office of Research and DevelopmentIcahn School of Medicine at Mount Sinai; Weill Medical College of Cornell University and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Westview Physician CollaborativeCompletedAdverse Drug EventsCanada
-
University Hospital, AkershusHospital Pharmacy Enterprise, South Eastern NorwayUnknownIntensive Care Unit | Medicines ReconciliationNorway
-
University of IbadanCompletedIntervention StudyNigeria
-
University Hospital, GrenobleUnknown
-
Helsinki University Central HospitalRecruitingChronic Disease | Medication Adherence | Medication NonadherenceFinland
-
Istituto Scientifico Romagnolo per lo Studio e...Recruiting
-
Assistance Publique - Hôpitaux de ParisAgence Regionale de Sante d'Ile de FranceActive, not recruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Hypertension Chronic ThromboembolicFrance